Literature DB >> 18844596

Smallpox vaccines for biodefense: need and feasibility.

Andrew W Artenstein1, John D Grabenstein.   

Abstract

Smallpox, eradicated as a cause of natural disease through an intensive global effort in the later part of the 20th Century, has resurfaced as a possible agent of bioterrorism. For this reason, there is renewed interest in smallpox vaccines. Live vaccinia virus, an orthopoxvirus related to smallpox, has a long and successful clinical track record as an effective smallpox vaccine; however, its use is associated with uncommon yet serious adverse events. This has led to a surge of recent research into newer-generation smallpox vaccines with improved safety profiles and retained efficacy. This article will review the history of smallpox vaccines, assess the status of newer-generation vaccines and examine the overall risk-versus-benefit profile of smallpox vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18844596     DOI: 10.1586/14760584.7.8.1225

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  20 in total

1.  Genome-wide genetic associations with IFNγ response to smallpox vaccine.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2012-06-03       Impact factor: 4.132

Review 2.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

3.  Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.

Authors:  Joanne Domenico; Joseph J Lucas; Mayumi Fujita; Erwin W Gelfand
Journal:  Int Arch Allergy Immunol       Date:  2012-01-26       Impact factor: 2.749

4.  Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Authors:  Jeffrey S Kennedy; Marc Gurwith; Cornelia L Dekker; Sharon E Frey; Kathryn M Edwards; Julie Kenner; Michael Lock; Cyril Empig; Shigeru Morikawa; Masayuki Saijo; Hiroyuki Yokote; Kevin Karem; Inger Damon; Mark Perlroth; Richard N Greenberg
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 5.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

6.  In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.

Authors:  Eric M Bachelder; Tristan T Beaudette; Kyle E Broaders; Jean M J Fréchet; Mark T Albrecht; Alfred J Mateczun; Kristy M Ainslie; John T Pesce; Andrea M Keane-Myers
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

Review 7.  The evolutionary biology of poxviruses.

Authors:  Austin L Hughes; Stephanie Irausquin; Robert Friedman
Journal:  Infect Genet Evol       Date:  2009-10-13       Impact factor: 3.342

8.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

Review 9.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 10.  The immunology of smallpox vaccines.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Curr Opin Immunol       Date:  2009-06-11       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.